Universities Step Up Their Role in Regional Economic Development

Regional Innovation Ecosystem Dynamics:

• Innovation clusters (e.g., Silicon Valley, Research Triangle) rely on the spatial proximity of universities, which generate and convey knowledge more efficiently than dispersed entities.
• The "regional innovation life cycle" identifies universities as the primary catalyst for commercialization, entrepreneurship, and industry clustering.
• Geographic contiguity of assets (industry, academia, capital) is a critical determinant of cluster success, which is currently lacking in many regions despite high asset availability.

State Performance and Rankings:

• Massachusetts has ranked #1 in the Milken Institute's State Technology and Science Index every year since 2002.
• Maryland ranked #2 since 2008; California ranked #3.
• Rankings adjust for economy size and measure R&D assets (NIH funding, academic/industry R&D) and human capital commercialization capacity.

Institutional Case Studies and Challenges:

• Johns Hopkins University:
  • Inherited a cultural barrier where "publishing was noble, but patenting was not," despite 35 years as the top NIH funding recipient.
  • Licensing revenue was ~$18M annually compared to ~$150M at Columbia, highlighting a commercialization gap.
  • Leadership shifted the narrative from revenue generation to societal impact, encouraging faculty to see commercialization as part of their responsibility.
  • Current Obstacle: Key assets (industry, research) are not geographically contiguous (e.g., MedImmune is 45 minutes away), requiring deliberate intervention to foster a cluster.
  • Initiatives: Launched entrepreneurship minors (30%+ of 5,000 undergrads), faculty boot camps, and a joint PhD program with MedImmune/AstraZeneca allowing students to work in industry for one year.
• Caltech:
  • Measures success by the transition of lab research to societal products (drugs, devices) rather than direct revenue.
  • Competitively hired an Entrepreneur-in-Residence (EIR) for 1–2 years to guide faculty in de-risking technologies and creating business cases.
  • Focuses on graduate-level entrepreneurship training, leveraging the fact that these students possess 10+ years of technical experience requiring commercialization tools.

Government and Policy Interventions:

• Massachusetts Life Sciences Initiative (2007–2008):
  • State invested $1B over 10 years to catalyze growth during the Great Recession.
  • Leverage: Spent ~$500M to leverage $1.8B in private investment and create thousands of jobs.
  • Strategy: Addressed "valley of death" funding gaps, provided infrastructure (e.g., sewage for Genzyme in Framingham), and enforced cross-institutional collaboration.
  • Inclusivity: Directed investment toward "gateway cities" (e.g., Framingham, Pittsfield) rather than just Cambridge to displace manufacturing and include non-PhD workforce development.
• Federal Role:
  • Government funding (NIH) is the foundational "goose that lays the golden eggs"; a 20% real-term budget contraction is cited as a critical threat.
  • Panelists propose federal matching funds (e.g., 10–20% of grants set aside for commercialization follow-on) to bridge the gap between basic research and venture capital.
• Risk Management:
  • Governments must tolerate higher failure rates to foster innovation, contrasting with standard political risk aversion.
  • Public funds should act as catalysts/gap-fillers, not substitutes for private capital, with strict clawbacks if job creation targets are missed.

Industry Perspectives and Metrics:

• MedImmune/AstraZeneca (Bahija Jalal):
  • Collaboration criteria: (1) Strength of science, (2) Cultural alignment and mutual respect, (3) Measurable deliverables beyond "talk."
  • Emphasizes that industry and academia must co-exist with "blue sky" research, which companies cannot fund but is essential for long-term discovery.
• Commercialization Efficiency:
  • From 1991–2004, $800B in US university federal funding generated 320,000 invention disclosures, 70,000 patents, 37,000 active licenses, and 9,000 startups.
  • Failure Rates: Only ~1 in 100 pharma compounds reaches approval; ~1 in 10 venture investments are significant hits.

Cultural and Educational Shifts:

• Faculty Tenure: A shift is occurring to recognize patents as a legitimate form of creative enterprise alongside publications, though implementation varies by school.
• Student Mindset: "Blue-sky" research and entrepreneurship are no longer mutually exclusive; students increasingly seek market-ready skills without abandoning their core majors.
• K-12 Deficit: A "crisis" in US K-12 numeracy and literacy is identified as a "glass ceiling" threatening the future human capital pipeline for innovation clusters.

Forward-Looking Recommendations:

• One-Page Summary of Key Proposals:
  • Ron Daniels: Align public leadership with a coherent, long-term (K-12 to commercialization) strategy; increase funding to bridge the "valley of death."
  • Fred Farina: Increase federal investment in commercialization follow-on funding; maintain a protected sector for blue-sky research.
  • Bahija Jalal: Prioritize deep collaboration while preserving blue-sky research capabilities.
  • Deval Patrick: Governments must model collaboration, ignore short-term election cycles (adopt 10-year horizons), and use "honest broker" funds to force cross-institutional partnerships.